Eli Lil­ly touts some mixed PhI­II re­sults for clus­ter headaches as Am­gen, No­var­tis prep a mar­ket-bust­ing move in mi­graine

With Am­gen and No­var­tis ea­ger­ly await­ing their PDU­FA date for the lead­ing CGRP mi­graine drug Aimovig lat­er this week, Eli Lil­ly is step­ping up with some mixed Phase III re­sults for its own con­tender in the field.

Christi Shaw

In a hit and a miss, Lil­ly re­searchers say that gal­canezum­ab scored on the pri­ma­ry end­point in a Phase III study of pa­tients suf­fer­ing from episod­ic, week­ly clus­ter headaches. Placed up against a place­bo, their drug achieved a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in clus­ter at­tacks — though the p val­ue of 0.036 was a long way from a stand­out grade. 

Lil­ly al­so not­ed that an­oth­er Phase III for chron­ic clus­ter headaches failed — though you can be sure the phar­ma gi­ant was far more ea­ger to high­light the pos­i­tive re­sults in its re­lease. And now Lil­ly ex­ecs are set­ting up talks with reg­u­la­tors about the way for­ward to the mar­ket.

Lil­ly has al­ready post­ed its pos­i­tive late-stage da­ta for this drug in suc­cess­ful­ly re­duc­ing mi­graines. CGRP drugs are wide­ly viewed as the up­com­ing stan­dard of care for this cat­e­go­ry of dis­ease, and Am­gen and No­var­tis aim to push hard to cap­i­tal­ize on their fron­trun­ner sta­tus — pro­vid­ed the FDA comes through as ex­pect­ed with an ap­proval with­in a cou­ple of days.

An­a­lysts have of­fered a $1.2 bil­lion peak sales es­ti­mate for Aimovig — mak­ing it a top-12 drug for this year — which il­lus­trates just how im­por­tant a ground­break­ing po­si­tion can be in drug de­vel­op­ment.

Lil­ly is in a fa­mil­iar po­si­tion fur­ther back in the field, as it awaits an FDA de­ci­sion some­time in the third quar­ter. But they should be next in line be­hind the Am­gen/No­var­tis team. Te­va’s ri­val fre­manezum­ab had been in line for a June de­ci­sion, then ear­li­er this month con­ced­ed that man­u­fac­tur­ing prob­lems would tem­porar­i­ly de­rail its pro­gram and push any ap­proval and mar­ket­ing launch fur­ther back in the year. And in March lit­tle Alder, which al­so has a con­tender in the mix, oust­ed its CEO and be­gan to re­struc­ture af­ter falling be­hind the lead­ers.

Eli Lil­ly has been scram­bling to beef up its on­col­o­gy pipeline with bolt-on deals this year. The phar­ma gi­ant has gained a num­ber of new ap­provals in re­cent years, but was se­ri­ous­ly de­layed on baric­i­tinib last year, be­fore the FDA abrupt­ly de­cid­ed to al­low their mar­ket­ing pitch to move through a re­view with­out a re­quired safe­ty tri­al.

“Clus­ter headache can be dif­fi­cult to eval­u­ate in clin­i­cal stud­ies, which has con­tributed to few avail­able treat­ment op­tions for clus­ter headache, of­ten con­sid­ered the most se­vere pain one can ex­pe­ri­ence,” said Christi Shaw, pres­i­dent of Lil­ly Bio-Med­i­cines. “The pos­i­tive re­sults in episod­ic clus­ter headache are tru­ly a land­mark mo­ment—both for peo­ple liv­ing with clus­ter headache and for our re­searchers at Lil­ly, many of whom have spent more than two decades re­search­ing and de­vel­op­ing in­no­v­a­tive, non-opi­oid treat­ment op­tions for dis­eases like mi­graine and clus­ter headache.”

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its Vascepa patents protected from generic drugmakers.

Amarin had been fighting to keep key patents under lock and key — and away from generic rivals — for another 10 years, but District Court Judge Miranda Du in Las Vegas ruled against the biotech. She ruled that:
(A)ll the Asserted Claims are invalid as obvious under 35 U.S.C.§ 103. Thus, the Court finds in favor of Defendants on Plaintiff’s remaining infringementclaim, and in their favor on their counterclaims asserting the invalidity of the AssertedClaims under 35 U.S.C. § 103.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

After providing an emergency approval to use malaria drugs against coronavirus with little actual evidence of their efficacy or safety in that setting, the FDA has already proven that it has set aside the gold standard when it comes to the pandemic. And now regulators have spelled out a new approach to speeding development that promises immediate responses in no uncertain terms — promising a program offering the ultimate high-speed pathway to Covid-19 drug approvals.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

The race to de­vel­op Covid-19 drugs and vac­cines is on — here’s what’s hap­pen­ing in the UK

Weeks away from the results of ongoing US and China trials testing its experimental antiviral remdesivir, Gilead is going to trial the failed Ebola drug in a small group of coronavirus patients in England and Scotland. The United Kingdom is also home to a range of other therapeutic efforts, as the pandemic rages on across the globe.

On Tuesday, Southampton, UK-based startup Synairgen kicked off a mid-stage placebo-controlled study testing its experimental drug, SNG001 — an inhaled formulation of interferon-beta-1a — that has previously shown to be safe and effective in improving lung function in asthma patients with a respiratory viral infection in a pair of Phase II trials.

‘There was a grow­ing weari­ness’: Rush­ing against a pan­dem­ic clock, As­pen Neu­ro­sciences se­cures $70M Se­ries A

Just before Christmastime, Howard Federoff got a tip from Washington: There was a new virus in China. And this one could be bad.

News report of the virus had not yet appeared. Federoff, a neuroscientist, was briefed because years before, he was vetted as part of a group — he didn’t give a name for the group — to consult for the US government on emerging scientific issues. His day job, though, was CEO of Aspen Neurosciences, a Parkinson’s cell therapy startup that days before had come out of stealth mode and gave word to investors they were hoping to raise $70 million. That, Federoff realized, would be difficult if a pandemic shut down the global economy.

FDA puts pe­di­atric aGVHD drug on pri­or­i­ty re­view lane — will they go vir­tu­al with the ad­comm?

Despite worries about regulatory delays due to new work arrangements under Covid-19, the FDA appears intent to go full speed ahead with its everyday work, not only granting priority review to a stem cell therapy for acute graft versus host disease but also plotting an advisory committee meeting for it.

With a PDUFA date of September 30, the journey of the drug — remestemcel-L, or Ryoncil — could shed light on the agency’s capacity to facilitate drug development unrelated to Covid-19.

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

President Trump has a new favorite Covid-19 drug.

After a conversation with Japanese Prime Minister Shinzo Abe, Politico reports, the president is pressuring the FDA to issue emergency use authorization for favipiravir, a flu drug that showed glimpses of success in China but remains unproven and carries a list of worrying side effects. The push comes after a week-plus in which the White House touted a potentially effective but unproven malaria medication despite the concerns of scientific advisors such as NIAID director Anthony Fauci. And Trump ally Rudy Giuliani has been talking up unproven cell therapy efforts on Twitter.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

ITeos nabs $125M as they prep Keytru­da com­bi­na­tion tri­al — if Covid-19 will let them

For iTeos, it turned out, $75 million could only last so long.

Two years after announcing their eye-catching Series B raise, the Belgian biotech is back with an even larger Series B-2: $125 million.

The now $175 million financing – $25 million of the first B round is considered part of the second – illustrates the vast capital available for those with promising new immuno-oncology compounds, particularly those that might be used in combination with existing therapies. In December, iTeos announced a collaboration with Merck to test its lead compound with Keytruda this year. The proceeds will push forward that trial and help fund the ongoing Phase I/II trials for that compound, EOS-850, and a second one, EOS-448.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.